Wednesday, May 09, 2018 9:43:55 PM
Does the manipulation of adipose derived autologous stem cell as is performed by USRM clinics enough for it to constitute a "drug" as defined by the regulations and thus bring it under the preview of the FDA?
KC and crew contend that it is not and have been looking for this fight since August of last year with their response to the warning letter. Not sure whether this injunction will be granted but we're definitely set for a legal showdown.
Either way, not good for business in the short term. In the long term, once this issue is resolved and if USRM comes out on top, USRM will cement it's place as the leader in the field. If USRM loses, well, there goes 33% of revenue stream until FDA figures out how to regulate this emerging field.
so, place your bets people.
Go USRM!!!
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM